- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
VolitionRX Reports Q4 Loss
Biotech company VolitionRX posts $6.3 million loss in latest quarter
Mar. 31, 2026 at 10:51pm
Got story updates? Submit your updates here. ›
VolitionRX Ltd., a biotech company based in Henderson, Nevada, reported a loss of $6.3 million in its fourth quarter, according to the latest earnings report.
Why it matters
VolitionRX is a publicly traded company focused on developing innovative cancer detection tests. Its quarterly financial results are closely watched by investors and analysts to gauge the company's progress and future prospects.
The details
The $6.3 million loss reported by VolitionRX for the fourth quarter was in line with analysts' expectations. The company attributed the loss to ongoing research and development expenses as it continues to advance its pipeline of cancer detection tests.
- VolitionRX reported its Q4 2025 financial results on March 31, 2026.
The players
VolitionRX Ltd.
A biotech company focused on developing innovative cancer detection tests. It is publicly traded on the NYSE.
The takeaway
While VolitionRX reported a sizable loss for the quarter, the results were in line with expectations as the company continues to invest heavily in research and development to advance its cancer detection technology. Investors will be closely watching the company's progress in the coming quarters.
